LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Accueil・Liste d'Actions・Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc

Fermé

SecteurSoins de santé

433.1 -0.04

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

432.05

Max

438.16

Chiffres clés
By Trading Economics
Revenu	-160M 1B
Ventes	-240M 3B
P/E Moyenne du Secteur	25.91 49.701
BPA	4.47
Marge bénéficiaire	34.531
Employés	6,400
EBITDA	-215M 1.1B

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+29.84% upside

Dividendes
By Dow Jones
Prochains Résultats	3 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	2.4B 111B
Ouverture précédente	433.14
Clôture précédente	433.1

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

428.545 / 498.65 Support & Résistance

Vertex Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

4 mai 2026, 20:57 UTC

Résultats

Vertex Pharmaceuticals Posts Higher 1Q Profit

12 févr. 2026, 21:47 UTC

Résultats

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

3 nov. 2025, 21:44 UTC

Résultats

Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs

5 août 2025, 00:05 UTC

Actions en Tendance

Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl

4 août 2025, 21:21 UTC

Résultats

Principaux Mouvements du Marché

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 août 2025, 20:45 UTC

Résultats

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 mai 2026, 20:02 UTC

Résultats

Vertex Pharmaceuticals Reiterates 2026 Guidance

4 mai 2026, 20:01 UTC

Résultats

Vertex Pharmaceuticals 1Q Net $1.03B >VRTX

4 mai 2026, 20:01 UTC

Résultats

Vertex Pharmaceuticals 1Q Rev $2.99B >VRTX

4 mai 2026, 20:01 UTC

Résultats

Vertex Pharmaceuticals 1Q Adj EPS $4.47 >VRTX

4 mai 2026, 20:01 UTC

Résultats

Vertex Pharmaceuticals 1Q EPS $4.02 >VRTX

12 févr. 2026, 21:13 UTC

Résultats

Vertex Pharmaceuticals Guidance Includes Immaterial Cost Impact From Tariffs in 2026 >VRTX

12 févr. 2026, 21:13 UTC

Résultats

Vertex Pharmaceuticals Sees FY26 Rev $12.95B-$13.1B >VRTX

12 févr. 2026, 21:01 UTC

Résultats

Vertex Pharmaceuticals 4Q Rev $3.19B >VRTX

12 févr. 2026, 21:01 UTC

Résultats

Vertex Pharmaceuticals 4Q Net $1.19B >VRTX

12 févr. 2026, 21:01 UTC

Résultats

Vertex Pharmaceuticals 4Q EPS $4.65 >VRTX

12 févr. 2026, 21:01 UTC

Résultats

Vertex Pharmaceuticals 4Q Adj EPS $5.03 >VRTX

3 nov. 2025, 21:05 UTC

Résultats

Vertex Pharmaceutic Sees 2025 Rev $11.9B-$12B >VRTX

3 nov. 2025, 21:02 UTC

Résultats

Vertex Pharmaceuticals 3Q EPS $4.20 >VRTX

3 nov. 2025, 21:02 UTC

Résultats

Vertex Pharmaceuticals 3Q Adj EPS $4.80 >VRTX

3 nov. 2025, 21:02 UTC

Résultats

Vertex Pharmaceuticals 3Q Net $1.08B >VRTX

3 nov. 2025, 21:02 UTC

Résultats

Vertex Pharmaceuticals 3Q Rev $3.08B >VRTX

5 août 2025, 20:44 UTC

Résultats

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 août 2025, 18:17 UTC

Résultats

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 août 2025, 15:25 UTC

Résultats

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5 août 2025, 14:12 UTC

Résultats

Vertex Stock Tumbles After Strong Earnings. What's Spooking Investors. -- Barrons.com

5 août 2025, 11:27 UTC

Résultats

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 août 2025, 10:55 UTC

Résultats

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 août 2025, 10:36 UTC

Résultats

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 août 2025, 10:18 UTC

Résultats

Vertex Stock Tumbles 15% After Strong Earnings. What's Spooking Investors. -- Barrons.com

Comparaison

Variation de prix

Vertex Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

29.84% hausse

Prévisions sur 12 Mois

Moyen 562.9 USD 29.84%

Haut 641 USD

Bas 436 USD

Basé sur 24 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

24 ratings

Achat

Maintien

Vente

Basé sur 24 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

428.545 / 498.65Support & Résistance

Recent bearish events outweigh bullish events.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.